Resmed (RMD) Research & Development (2009 - 2026)

Resmed (RMD) has 18 years of Research & Development data on file, last reported at $94.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 12.3% year-over-year to $94.3 million; the trailing twelve-month figure through Mar 2026 stood at $359.0 million (up 10.22% YoY), and the FY2025 full-year result was $331.3 million, up 7.73% from the prior year.
• Research & Development for Q1 2026 stood at $94.3 million, up from $91.0 million in the prior quarter.
• Across five years, Research & Development topped out at $94.3 million in Q1 2026 and bottomed at $63.2 million in Q3 2022.
• The 5-year median for Research & Development is $78.1 million (2023), against an average of $78.2 million.
• The widest annual swing landed in 2023, when Research & Development increased 21.5%; it then gained 0.83% in 2024.
• A 5-year view of Research & Development shows it stood at $69.9 million in 2022, then advanced by 5.73% to $73.9 million in 2023, then grew by 10.14% to $81.4 million in 2024, then grew by 11.79% to $91.0 million in 2025, then rose by 3.63% to $94.3 million in 2026.
• The last three Research & Development figures came in at $94.3 million (Q1 2026), $91.0 million (Q4 2025), and $87.3 million (Q3 2025), per Business Quant data.

Peer Comparison